Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23887343 | 0.87 | PIK3CA (0.37) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30064040 | 0.87 | PIK3CA (0.39) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL24913406 | 0.87 | PIK3CA (0.37) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23887051 | 0.87 | PIK3CA (0.39) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30434136 | 0.86 | SIRT2 (0.38) | CCNE2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL23887120 | 0.86 | CCNE2 (0.33) | PIK3CAPIK3CBPIK3CDPIK3CGCCNE2 | |
| SCHEMBL23887048 | 0.83 | PIK3CA (0.34) | PIK3CACCNE2CDK1CDK4CCNB1 | |
| SCHEMBL29202685 | 0.82 | PIK3CA (0.34) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL30770733 | 0.82 | PIK3CA (0.34) | PIK3CAPIK3CBPIK3CDPIK3CGPRKDC | |
| SCHEMBL23887280 | 0.82 | GPR35 (0.35) | ELANECCNE2CDK1CDK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514784-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119301106-A | Allosteric benzopyrone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-4444714-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| CN-118742545-A | Fused heterocyclic compounds as PI3K alpha inhibitors | 南京征祥医药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-117769546-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4334312-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693506-A | Allosteric ketone inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117597343-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212693-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023104111-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-06-15 | — | — | WO | disclosed |
| CN-115956075-A | Allosteric enone inhibitors of phosphoinositide 3-kinases (PI 3 ks) for the treatment of diseases associated with PI3K modulation | 佩特拉制药公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4126851-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | Petra Pharma Corporation (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2021202964-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | PETRA PHARMA CORPORATION (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885 |
| US-20230017140-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 16/4885PIK3CD 6/4885 |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | PIK3CA 1/4885PIK3CB 17/4885PIK3CD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.